2-amino-4-furan-2-yl-indeno[1,2-d]pyrimidin-5-one | 713514-52-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-amino-4-furan-2-yl-indeno[1,2-d]pyrimidin-5-one
• 英文别名: 2-amino-4-(furan-2-yl)-5H-indeno[1,2-d]pyrimidin-5-one；2-amino-4-(furan-2-yl)indeno[1,2-d]pyrimidin-5-one
• CAS: 713514-52-4
• 化学式: C₁₅H₉N₃O₂
• 分子量: 263.255
• InChiKey: KHOCZGQEVMEBSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  盐酸胍 、 2-(2-furylmethylene)indane-1,3-dione 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 2-amino-4-furan-2-yl-indeno[1,2-d]pyrimidin-5-one
  参考文献：
  名称：

  Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists

  摘要：

  A novel series of arylindenopyrimidines were identified as A(2A) and A(1) receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson's disease when dosed orally. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.042

文献信息

• [EN] ARYLINDENOPYRIDINES AND ARYLINDENOPYRIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONIST<br/>[FR] ARYLINDENOPYRIDINES ET ARYLINDENOPYRIMIDINES ET LEUR UTILISATION EN TANT QU'ANTAGONISTE DES RECEPTEURS D'ADENOSINE A2A
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2005042500A1

  公开（公告）日：2005-05-12

  This invention provides novel arylindenopyridines and arylindenopyrimidines of formula (I), (II) wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.

  该发明提供了新颖的芳基吲哚吡啶和芳基吲哚嘧啶，化学式为(I)、(II)，其中R1、R2、R3、R4和X如上定义，并包括同样的药物组合物，用于治疗通过拮抗腺苷A2a受体改善的疾病。该发明还提供了使用这些化合物和药物组合物的治疗和预防方法。
• Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
  申请人：——

  公开号：US20040127510A1

  公开（公告）日：2004-07-01

  This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: 1 wherein R 1 , R 2 , R 3 , R 4 , and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.

  这项发明提供了新颖的芳基吲哚吡啶和芳基吲哚嘧啶，化学式如下：1其中R1、R2、R3、R4和X如上所定义，以及包含它们的药物组合物，用于治疗通过拮抗腺苷A2a受体改善的疾病。该发明还提供了使用这些化合物和药物组合物的治疗和预防方法。
• Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists
  作者：Brian C. Shook、Stefanie Rassnick、Daniel Hall、Kenneth C. Rupert、Geoffrey R. Heintzelman、Kristen Hansen、Devraj Chakravarty、James L. Bullington、Robert H. Scannevin、Brian Magliaro、Lori Westover、Karen Carroll、Lisa Lampron、Ronald Russell、Shawn Branum、Kenneth Wells、Sandra Damon、Scott Youells、Xun Li、Mel Osbourne、Keith Demarest、Yuting Tang、Kenneth Rhodes、Paul F. Jackson

  DOI：10.1016/j.bmcl.2010.03.042

  日期：2010.5

  A novel series of arylindenopyrimidines were identified as A(2A) and A(1) receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson's disease when dosed orally. (C) 2010 Elsevier Ltd. All rights reserved.
• ARYLINDENOPYRIDINES AND ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：EP1673354A1

  公开（公告）日：2006-06-28
• JP2007521243A
  申请人：——

  公开号：JP2007521243A

  公开（公告）日：2007-08-02